Updated:
Century Therapeutics
Century Therapeutics develops allogeneic iPSC-derived NK and T cell therapies. The therapies are designed to achieve greater effectiveness, tolerability,...
Overview
Century Therapeutics develops allogeneic iPSC-derived NK and T cell therapies. The therapies are designed to achieve greater effectiveness, tolerability, accessibility, and affordability than existing cell therapies.
General information
Firm type
Asset Manager
Location
Region
Europe
Country
United States
City
Philadelphia
Corporate office
Leverkusen, Philadelphia, Madison, Germany
Additional offices
Branchburg · Boston · Leverkusen
Sector focus
Frequently asked questions
What is Century Therapeutics' core technology platform?
Century uses induced pluripotent stem cells (iPSCs) as a starting material to manufacture allogeneic NK and T cell therapies. The platform relies on a single clonal master cell bank that is gene-edited with multiple transgenes for enhanced persistence, tumor targeting, and allo-evasion. This approach aims to produce an off-the-shelf product that avoids the patient-specific manufacturing required by autologous CAR-T therapies.
What is the current lead clinical candidate for Century Therapeutics?
The company's lead disclosed program is CNTY-101, an allogeneic, iPSC-derived NK cell therapy targeting CD19. The candidate incorporates multiple gene edits, including a CD19-targeting CAR, IL-15 pathway support, and allo-evasion strategies designed to prevent host rejection. It is being evaluated for relapsed or refractory B-cell malignancies.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: